<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>56(5)</volume><submitter>Fukumi T</submitter><funding>Japan Society of Transfusion Medicine</funding><pubmed_abstract>&lt;h4>Introduction&lt;/h4>No established criteria exist for assessing the effectiveness of granulocyte transfusion (GTX) or biomarkers for predicting fatal infections in neutropenia. This study aimed to assess whether a novel sepsis marker, presepsin (P-SEP), is a useful prognostic indicator during GTX.&lt;h4>Methods&lt;/h4>We collected frozen serum from 8 patients who had undergone GTX between September 2022 and October 2023 and measured their P-SEP levels. We compared these results with clinical records and assessed the alterations before and after GTX and their association with prognosis.&lt;h4>Results&lt;/h4>The post-transfusion neutrophil count increased in all cases. In 5 of 8 patients (62.5%), P-SEP levels were reduced 1 day after GTX. Pretransfusion P-SEP levels were statistically significantly low</pubmed_abstract><journal>Laboratory medicine</journal><pagination>469-477</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12417075</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Markedly elevated serum level of presepsin in agranulocytosis with hematologic malignancy: A potential prognostic factor in a single-institution retrospective study after granulocyte transfusion.</pubmed_title><pmcid>PMC12417075</pmcid><pubmed_authors>Matsuoka KI</pubmed_authors><pubmed_authors>Asano N</pubmed_authors><pubmed_authors>Asada N</pubmed_authors><pubmed_authors>Maeda Y</pubmed_authors><pubmed_authors>Fujii K</pubmed_authors><pubmed_authors>Seike K</pubmed_authors><pubmed_authors>Ennishi D</pubmed_authors><pubmed_authors>Kobayashi H</pubmed_authors><pubmed_authors>Fujii N</pubmed_authors><pubmed_authors>Fukumi T</pubmed_authors><pubmed_authors>Fujiwara H</pubmed_authors><pubmed_authors>Otsuka F</pubmed_authors><pubmed_authors>Kondo T</pubmed_authors><pubmed_authors>Kitamura W</pubmed_authors><pubmed_authors>Ikeuchi K</pubmed_authors><pubmed_authors>Yamamoto A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Markedly elevated serum level of presepsin in agranulocytosis with hematologic malignancy: A potential prognostic factor in a single-institution retrospective study after granulocyte transfusion.</name><description>&lt;h4>Introduction&lt;/h4>No established criteria exist for assessing the effectiveness of granulocyte transfusion (GTX) or biomarkers for predicting fatal infections in neutropenia. This study aimed to assess whether a novel sepsis marker, presepsin (P-SEP), is a useful prognostic indicator during GTX.&lt;h4>Methods&lt;/h4>We collected frozen serum from 8 patients who had undergone GTX between September 2022 and October 2023 and measured their P-SEP levels. We compared these results with clinical records and assessed the alterations before and after GTX and their association with prognosis.&lt;h4>Results&lt;/h4>The post-transfusion neutrophil count increased in all cases. In 5 of 8 patients (62.5%), P-SEP levels were reduced 1 day after GTX. Pretransfusion P-SEP levels were statistically significantly low</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-01T16:09:36.639Z</modification><creation>2026-04-08T14:04:40.066Z</creation></dates><accession>S-EPMC12417075</accession><cross_references><pubmed>40139248</pubmed><doi>10.1093/labmed/lmae118</doi></cross_references></HashMap>